MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze GMAB →
    • FindStock Picks / Stock Screener
    • Value · GMABIntrinsic Value Calculator
    • Invest · GMABInvestment Case
    • Hold · GMAB5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
GMAB stock logo

GMAB

Genmab A/S

$50.6
-0.75
 (-1.46%)
Exchange:  NASDAQ
Market Cap:  31.2B
Shares Outstanding:  621.511M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  BiotechnologyView industry performance
   
CEO:  Jan van de Winkel
Full Time Employees:  3244
Address: 
Carl Jacobsens Vej 30
Copenhagen
CD
2500
DK
Website:  https://www.genmab.com
Genmab A/S, a biotechnology firm based in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody-based treatments for various forms of cancer and other serious conditions. The company currently commercializes several key therapeutic antibodies. DARZALEX (daratumumab) is utilized in the treatment of multiple myeloma (MM), specific non-MM blood cancers, and AL amyloidosis. Other marketed offerings include teprotumumab for thyroid eye disease, ofatumumab, which addresses chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic non-small cell lung cancer (NSCLC) as well as gastric or esophageal cancers. Genmab maintains an extensive and active development pipeline, featuring a broad range of experimental therapies. This includes GEN1047, tisotumab vedotin (targeting cervical, ovarian, and other solid cancers), and bispecific antibodies such as DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, which are engineered for solid tumors. Epcoritamab is being developed for relapsed/refractory diffuse large B-cell lymphoma and CLL, while HexaBody-CD38 and DuoHexaBody-CD37 are designed to treat hematological malignancies. Further assets in the pipeline encompass Teclistamab, currently in Phase 2 clinical trials for vaso-occlusive crises, Camidanlumab tesirine for Hodgkin lymphoma and solid tumors, JNJ-64007957 and JNJ-64407564 for MM, PRV-015 for celiac disease, Mim8 for haemophilia A, and Lu AF82422 for multiple system atrophy. Additionally, the company is engaged in approximately 20 pre-clinical research programs. Strategic collaborations are a cornerstone of Genmab’s operational model. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of mRNA-based antibody products, with argenx for the discovery of novel therapeutic antibodies in immunology and oncology, and with AbbVie for the development of epcoritamab. Other notable collaborators include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was established in 1999 and is headquartered in Copenhagen, Denmark.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
GMGMAB logoGMABGenmab A/S31.2B42.940.210.3%
ININSM logoINSMInsmed Incorporated31.0B——-32.8%
ROROIV logoROIVRoivant Sciences Ltd.28.0B——-11.8%
RVRVMD logoRVMDRevolution Medicines, Inc.34.9B——-43.9%
UTUTHR logoUTHRUnited Therapeutics Corporation23.6B19.422.516.8%
ININCY logoINCYIncyte Corporation23.4B54.636.26.0%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/11/05 — 3 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue16,474,00021,526,0003,722,933.872
Gross Profit16,248,00020,541,0003,413,690.171
EBITDA6,000,618.7639,697,0001,337,053.667
Operating Income5,321,0006,703,0001,250,985.843
Net Income4,352,0007,844,000963,759.493

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets35,289,00045,811,00081,858,700.280
Total Liabilities3,679,0009,114,00044,677,948.279
Total Stockholders Equity31,610,00036,697,00037,180,752
Total Debt770,0001,029,00035,355,734.754
Cash and Cash Equivalents14,867,0009,858,00010,905,590.846

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow7,380,0007,771,0001,186,935.368
Capital Expenditure-376,000-187,000-37,029.182
Free Cash Flow7,004,0007,584,0001,149,906.186
Net Income5,637,0007,844,000963,759.493
Net Change in Cash4,974,000-5,009,000345,325.277

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)8,260,659.838Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)9,338,104.744Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)8,630,744.444Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)2,903,793.737Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)3,371,636.789Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)3,064,489.614Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)2,160,033.845Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)2,531,274.871Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)2,287,548.621Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)1,445,525.211Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)1,634,066.297Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)1,510,285.973Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)3.650Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)4.040Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)3.450Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)14Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)11Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
3.122B  ?P/S
 (TTM)
: 
7.29
?Net Income
 (TTM)
: 
1.138B  ?P/E
 (TTM)
: 
42.85
?Enterprise Value
 (TTM)
: 
34.727B  ?EV/FCF
 (TTM)
: 
41.1
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
12.26%  ?ROIC
 (TTM)
: 
10.27%
?Net Debt
 (TTM)
: 
-2.787B  ?Debt/Equity
 (TTM)
: 
0.82
?P/B
 (TTM)
: 
4.93  ?Current Ratio
 (TTM)
: 
2.45

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
40.16Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates GMAB intrinsic value between $45.05 – $47.71 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate GMAB Intrinsic Value

Common questions about GMAB valuation

Is Genmab A/S (GMAB) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Genmab A/S (GMAB) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is GMAB a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether GMAB trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is GMAB’s P/E ratio?

You can see GMAB’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for GMAB?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is GMAB a good long-term investment?

Whether GMAB fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Genmab A/S

  • Genmab A/S intrinsic value calculatorEstimate what the business is worth
  • Genmab A/S 5-year outlookWhat has to go right, and what could go wrong
GMAB

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-1.46
MarketSnap

Trading Metrics:

Open: 51.69   Previous Close: 51.35
Day Low: 50.32   Day High: 51.72
Year Low: 23.62   Year High: 59.97
Price Avg 50: 42.62   Price Avg 200: 31.92
Volume: 2.793M   Average Volume: 3.679M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Grant of Restricted Stock Units and Warrants to Employees in Genmab
24-09-2026 14:32
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
10-11-2026 17:57
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Genmab A/S (GMAB) Q3 2026 Earnings Call Transcript
05-11-2026 17:54
Genmab A/S (GMAB) Q3 2026 Earnings Call Transcript
A little-known biotech's high-stakes cancer bet just paid off and its shares doubled
03-11-2026 04:35
A little-known biotech's high-stakes cancer bet just paid off and its shares doubled
Genmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards Transcript
28-10-2026 17:30
Genmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards Transcript
Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches
28-10-2026 17:05
Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Pricing

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze GMAB →
    • FindStock Picks / Stock Screener
    • Value · GMABIntrinsic Value Calculator
    • Invest · GMABInvestment Case
    • Hold · GMAB5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Plans
    • Settings
    • Public profile ↗
  • Log in
  • Log out

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.